APD334

( DrugBank: - / KEGG DRUG: - )


5 diseases
IDDisease name (Link within this page)Number of trials
93Primary biliary cholangitis1
96Crohn disease32
97Ulcerative colitis90
IDDisease name (Link within this page)Number of trials
98Eosinophilic gastro-intestinal disorder3
269Pyogenic arthritis1

93. Primary biliary cholangitis


Clinical trials : 371 / Drugs : 286 - (DrugBank : 56) / Drug target genes : 35 - Drug target pathways : 105 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

96. Crohn disease


Clinical trials : 2,888 / Drugs : 1,678 - (DrugBank : 247) / Drug target genes : 193 - Drug target pathways : 234 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

97. Ulcerative colitis


Clinical trials : 3,566 / Drugs : 2,369 - (DrugBank : 339) / Drug target genes : 210 - Drug target pathways : 245 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

98. Eosinophilic gastro-intestinal disorder


Clinical trials : 222 / Drugs : 226 - (DrugBank : 48) / Drug target genes : 48 - Drug target pathways : 146 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

269. Pyogenic arthritis


Clinical trials : 35 / Drugs : 44 - (DrugBank : 17) / Drug target genes : 12 - Drug target pathways : 91 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries